K
Kadence Bio is a clinical-stage life sciences company developing novel therapeutics for sexual and mental health conditions. The company's lead asset, KH-001, is in development as the first FDA-approved treatment for premature ejaculation. Kadence Bio also maintains a pipeline of compounds targeting various mood disorders.
Kent, United States
Updated 2 months ago
Funding
$9.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Kadence Bio is a clinical-stage life sciences company developing novel therapeutics for sexual and mental health conditions. The company's lead asset, KH-001, is in development as the first FDA-approved treatment for premature ejaculation. Kadence Bio also maintains a pipeline of compounds targeting various mood disorders.